Using aggregated site features computed with the MPsQ to allow a better monitoring of sites in clinical trials

November 3, 2023

Using aggregated site features computed with the MPsQ to allow a better monitoring of sites in clinical trials Objective:   The MPsQ is an assessment characterizing the profile of the subjects participating to a Randomized Controlled Trial (RCT) to predict their behaviors in the study (placebo response, adherence, …). This analysis aimed to determine whether individual responses collected through the MPsQ could

Type: Scientific Poster

Authors: Arthur Ooghe, Samuel Branders, Jérôme Paul, Dominique Demolle, Alvaro Pereira

Date: November 9, 2023

Conference: CNS Summit 2023

Using Artificial Intelligence-based Methods to Address the Placebo Response in Clinical Trials

March 31, 2023

Cognivia team members contribute critical elements to a recent paper published in Innovations in Clinical Neuroscience. Cognivia co-authored a recent paper published in Innovations in Clinical Neuroscience. The paper, “Using Artificial Intelligence-based Methods to Address the Placebo Response in Clinical Trials,” was a collaborative effort by leaders in artificial intelligence and machine learning, as well as their applications within

Type: White Paper

Date: August 2, 2022

Conference: ISCTM

Accounting for the high reduction of power due to floor effect in design of randomised controlled trials

March 6, 2023

Purpose  Outcomes in Randomized Controlled Trials (RCT) are often computed as changes from baseline of finite scales (e.g., pain assessments going from 0 to 10). When subjects receive effective treatment over time they may reach the limit of a finite scale. In that case, the score limitation at the bottom of the finite scale, called

Type: Scientific Poster

Authors: A. Ooghe, S. Branders, J. Paul, A. Pereira Tools4Patient s.a. (dba Cognivia)

Date: March 18, 2023

Conference: OARSI 2023

Leveraging historical data to optimize the number of covariates and their explained variance in the analysis of randomized clinical trials

January 11, 2022

The amount of data collected from patients involved in clinical trials is continuously growing. All baseline patient characteristics are potential covariates that could be used to improve clinical trial analysis and power. However, the limited number of patients in phases I and II studies restricts the possible number of covariates included in the analyses. In

Type: Scientific Publication

Authors: Samuel Branders, Alvaro Pereira, Guillaume Bernard, Marie Ernst, Jamie Danenberg, Adelin Albert

Date: December 13, 2021

Conference: Statistical Methods in Medical Research Journal

Impact of excluding highly variable pain subjects on the treatment estimation

November 8, 2021

The baseline pain variability (BPV) has often been presented as positively correlating with the placebo response (PR) and associated with a lack of consistency in the subjects’ pain evaluation. Excluding high BPV subjects should then improve the precision of the treatment response. Another common method to increase the essay sensitivity is to adjust the analysis for covariates

Type: Scientific Poster

Authors: Arthur Ooghe, Samuel Branders, Alvaro Pereira

Date: November 8, 2021

Conference: CNS Summit

Leveraging historical data for covariate adjustment in the analysis of randomized clinical trials

October 26, 2021

Scientific Poster presented on October 2021 at the Annual Meeting of the Royal Statistical Society of Belgium. The amount of data collected from patients involved in clinical trials is continuouslygrowing. All baseline patient characteristics are potential covariates that could be used to improve clinical trial analysis and power. However, the limited number of patients in phases

Type: Scientific Poster

Authors: Samuel Branders, Alvaro Pereira, Guillaume Bernard,Marie Ernst, Adelin Albert

Date: October 21, 2021

Conference: Royal Statistical Society of Belgium